Entrada Therapeutics Inc (NASDAQ:TRDA) — Market Cap & Net Worth
Market Cap & Net Worth: Entrada Therapeutics Inc (TRDA)
Entrada Therapeutics Inc (NASDAQ:TRDA) has a market capitalization of $260.27 Million ($260.27 Million) as of June 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15586 globally and #3624 in its home market, demonstrating a 6.91% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Entrada Therapeutics Inc's stock price $6.81 by its total outstanding shares 38219232 (38.22 Million). Review Entrada Therapeutics Inc (TRDA) total liabilities to assess the company's total debt and financial obligations.
Entrada Therapeutics Inc Market Cap History: 2021 to 2026
Entrada Therapeutics Inc's market capitalization history from 2021 to 2026. Data shows change from $654.31 Million to $260.27 Million (-23.76% CAGR).
Index Memberships
Entrada Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.01% | #419 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #1507 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.02% | #213 of 263 |
Weight: Entrada Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Entrada Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Entrada Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.14x
Entrada Therapeutics Inc's market cap is 3.14 times its annual revenue
Latest Price to Earnings (P/E) Ratio
10.07x
Entrada Therapeutics Inc's market cap is 10.07 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $516.72 Million | $25.26 Million | -$87.46 Million | 20.46x | N/A |
| 2023 | $576.73 Million | $129.01 Million | -$6.68 Million | 4.47x | N/A |
| 2024 | $660.81 Million | $210.78 Million | $65.63 Million | 3.14x | 10.07x |
Competitor Companies of TRDA by Market Capitalization
Companies near Entrada Therapeutics Inc in the global market cap rankings as of June 19, 2026.
Key companies related to Entrada Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Entrada Therapeutics Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Entrada Therapeutics Inc's market cap moved from $654.31 Million to $ 260.27 Million, with a yearly change of -23.76%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $260.27 Million | -33.75% |
| 2025 | $392.89 Million | -40.54% |
| 2024 | $660.81 Million | +14.58% |
| 2023 | $576.73 Million | +11.61% |
| 2022 | $516.72 Million | -21.03% |
| 2021 | $654.31 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Entrada Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $260.27 Million USD |
| MoneyControl | $260.27 Million USD |
| MarketWatch | $260.27 Million USD |
| marketcap.company | $260.27 Million USD |
| Reuters | $260.27 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Entrada Therapeutics Inc
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV")-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a varie… Read more